1. T2DM, CV Safety, and Efficacy: DPP-4 Inhibitors in focus

2. DPP-4 Inhibitor CV Outcomes Trials in T2DM

3. T2DM CV Outcomes Trials From the DPP-4 Inhibitor Class

4. SAVOR-TIMI 53: Primary Endpoint

5. SAVOR-TIMI 53: Hospitalization for HF

6. EXAMINE: Primary Endpoint

7. EXAMINE: Hospitalization for HF

8. TECOS: Study Design

9. TECOS: Effect of Sitagliptin vs Placebo on CV Outcomes in T2DM

10. TECOS: Hospitalization for HF

11. DPP-4 Inhibitors: Hypoglycemia

12. DPP-4 Inhibitors: Pancreatitis

13. Future DPP-4 CV Outcomes Trials in T2DM

14. Managing T2DM: incorporating injectable fixed-dose combinations

15. Fixed-dose Combinations

16. Why Combine Basal Insulin and GLP-1 RAs?

17. DUAL-I: HbA1c Comparison

18. DUAL-I: Percentage of Patients to Target HbA1c

19. DUAL-I: Change in Body Weight

20. DUAL-I: Confirmed Hypoglycemia

21. DUAL-I: Nausea Over 26 Weeks

22. Addition of Insulin to GLP-1 RA and Addition of GLP-1 RA to Insulin in T2DM

23. When and How Should We Use Combination Therapies?

24. T2DM, CV SAFETy, and efficacy: GLP-1 Receptor Agonists in focus

31. ELIXA: Severe Symptomatic Hypoglycemia

35. T2DM, CV SAFETy, and efficacy: SGLT2 Inhibitors in focus

36. EMPA-REG OUTCOME

37. EMPA-REG OUTCOME: Study Design

38. EMPA-REG OUTCOME: Effect of Empagliflozin vs Placebo on the Primary Composite Outcome

39. EMPA-REG OUTCOME: Effect of Empagliflozin vs Placebo on CV Death

40. EMPA-REG OUTCOME: Effect of Empagliflozin vs Placebo on Individual CV Endpoints

41. EMPA-REG OUTCOME: Effect of Empagliflozin vs Placebo on All-cause Mortality

42. EMPA-REG OUTCOME: Effect of Empagliflozin vs Placebo on HF Hospitalization

43. Future SGLT2 Inhibitor CV Outcomes Trials